The 2025 List of Innovative Procedures Outside the Nomenclature (LAHN) was published in France

The Repository of Innovative Procedures outside the Nomenclature of Biology and Anatomopathology (RIHN) is an innovative payment scheme that provides temporary funding for IVD tests until sufficient evidence is available for inclusion in the Nomenclature of Medical Laboratory Procedures (NABM) or Common Classification of Medical Procedures (CCAM) for regular reimbursement. Tests included in the RIHN are financed outside the statutory health insurance system through the research and innovation budget (MERRI), which forms part of the MIGAC funds distributed by the Ministry of Health. 

With the RIHN reform started in 2023, a new List of Innovative Procedures Outside the Nomenclature (LAHN) was introduced in 2024, combining tests funded via the List of innovative tests and the Supplementary List of tests no longer considered innovative. Coverage in LAHN is limited to five years, with an annual 20% tariff reduction starting January 1, 2025. The French National Authority for Health (HAS) evaluates tests on LAHN to decide whether they can be included in the NABM and CCAM.

On August 5, 2025, the Ministry of Labor, Health, Solidarity, and Families published the 2025 version of LAHN, applicable from January 1 to December 31, 2025. Unlike 2024 version, the 2025 LAHN provides no tariffs for the tests.

Fourteen new “duplicating codes” were introduced, corresponding to existing LAHN codes but restricted to clinical indications positively assessed by HAS. These codes are exempt from the annual tariff reduction. For each code, a link to the relevant HAS assessment is provided. Some examples of the newly introduced duplicating codes are provided below: 

Sub-chapter 14-3-1 “Postnatal Constitutional Genetics”:

• V004 “Next-generation sequencing (NGS) package < 20 kb (index case) - Indications assessed by the HAS”;
• V005 “Next-generation sequencing (NGS) package > 20 kb and < 100 kb (index case) - Indications assessed by the HAS”;
• V006 “Next-generation sequencing (NGS) package > 100 kb and < 500 kb (index case) - Indications assessed by the HAS”.

Furthermore, 19 codes were removed, including ten codes removed due to registration for regular reimbursement in the NABM, CCAM, or both nomenclatures; seven codes were deleted following HAS assessment with insufficient actual benefit; two codes will be included in the gene panels (no longer considered as stand-alone tests).

Other modifications concerned comments or coding notes clarifying indications for several existing codes.

See the details in French here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.